(Q38343192)

2 September 2017

Disease protection and interleukin-10 induction by endogenous interferon-β in multiple sclerosis? (English)

1 reference

2 September 2017

0 references

Per Soelberg Sørensen

6

P Soelberg Sørensen

0 references

Dan Hesse

D Hesse

1

0 references

Martin Krakauer

M Krakauer

2

0 references

Finn Sellebjerg

F Sellebjerg

7

0 references

author name string

H Lund

3

1 reference

PubMed ID

20561040

2 September 2017

H B Søndergaard

4

1 reference

PubMed ID

20561040

2 September 2017

S J W Limborg

5

1 reference

2 September 2017

1 February 2011

1 reference

European Journal of Neurology

2 September 2017

1 reference

2 September 2017

18

1 reference

2 September 2017

2

1 reference

2 September 2017

266-272

1 reference

Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy

2 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03116.X

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03116.X

Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03116.X

Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03116.X

Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03116.X

Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03116.X

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03116.X

IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03116.X

Distinct and Nonredundant In Vivo Functions of IFNAR on Myeloid Cells Limit Autoimmunity in the Central Nervous System

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03116.X

Gene expression analysis of interferon-beta treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03116.X

Regulatory T cells in the control of inflammatory demyelinating diseases of the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03116.X

Th17: an effector CD4 T cell lineage with regulatory T cell ties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03116.X

Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03116.X

A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03116.X

T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03116.X

Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03116.X

10.1111/J.1468-1331.2010.03116.X

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference

PubMed ID

20561040